Firm Capable Of Producing Stem Cells For All Chinese Pediatric Leukemia Patients
This article was originally published in PharmAsia News
Executive Summary
Tianjin Angsai Cell and Genome Project, China's first umbilical stem-cell bank, says it is now able to produce stem cells on a large scale. The company has nearly 5,000 samples of mesenchymal umbilical-cord stem cell samples in stock. A spokesman for the Ministry of Health said a supply of 70,000 to 100,000 samples could treat all of China's pediatric leukemia patients who rely on cell transplants for their only cure. (Click here for more